NATURETIN-10

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NATURETIN-10 (NATURETIN-10).

How it works

Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water. It also reduces peripheral vascular resistance and has antihypertensive effects.

What the body does with it

Metabolism	Primarily hepatic via cytochrome P450 enzymes; minimal renal excretion of unchanged drug.
Excretion	Primarily renal (approximately 50-70% as unchanged drug); biliary/fecal elimination accounts for the remainder (30-50%).
Half-life	Terminal elimination half-life is approximately 2-4 hours; clinical context: dose adjustments may be needed in renal impairment.
Protein binding	Approximately 90% bound to plasma proteins (primarily albumin).
Volume of Distribution	0.3-0.5 L/kg; consistent with distribution primarily in extracellular fluid.
Bioavailability	Oral bioavailability is approximately 50-70% due to first-pass metabolism.
Onset of Action	Oral: 1-2 hours; clinical effect begins within 1-2 hours after administration.
Duration of Action	6-12 hours; clinical note: duration varies with renal function and dose.

Classification & Brands

Dosing & administration

Adults: 10 mg orally once daily.

Dosage form	TABLET
Renal impairment	GFR 30-89 mL/min: no adjustment; GFR <30 mL/min: not recommended.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Pediatric use	Not established for pediatric patients.
Geriatric use	Start at 5 mg once daily; titrate cautiously due to increased sensitivity.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NATURETIN-10 (NATURETIN-10).

Breastfeeding	No data on excretion in human milk. M/P ratio unknown. Potential for adverse effects in nursing infant, especially if high doses. Decision to breastfeed should consider maternal need and infant risk.
Teratogenic Risk	There is no data on NATURETIN-10 in pregnancy. Based on pharmacology, theoretical risk exists. First trimester: potential teratogenic effects cannot be ruled out. Second and third trimesters: may cause fetal renal impairment, oligohydramnios, and skull ossification delay.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Anuria","Hypersensitivity to bendroflumethiazide or sulfonamide-derived drugs","Hepatic coma or precoma","Severe renal impairment (CrCl <30 mL/min)"]

Clinical Precautions

Precautions

["Electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia)","Hyperuricemia and gout","Hyperglycemia in diabetic patients","Hypercalcemia","Photosensitivity","Exacerbation of systemic lupus erythematosus"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NATURETIN-10

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NATURETIN-10 (NATURETIN-10).

How it works

What the body does with it

Metabolism	Primarily hepatic via cytochrome P450 enzymes; minimal renal excretion of unchanged drug.
Excretion	Primarily renal (approximately 50-70% as unchanged drug); biliary/fecal elimination accounts for the remainder (30-50%).
Half-life	Terminal elimination half-life is approximately 2-4 hours; clinical context: dose adjustments may be needed in renal impairment.
Protein binding	Approximately 90% bound to plasma proteins (primarily albumin).
Volume of Distribution	0.3-0.5 L/kg; consistent with distribution primarily in extracellular fluid.
Bioavailability	Oral bioavailability is approximately 50-70% due to first-pass metabolism.
Onset of Action	Oral: 1-2 hours; clinical effect begins within 1-2 hours after administration.
Duration of Action	6-12 hours; clinical note: duration varies with renal function and dose.

Classification & Brands

Dosing & administration

Adults: 10 mg orally once daily.

Dosage form	TABLET
Renal impairment	GFR 30-89 mL/min: no adjustment; GFR <30 mL/min: not recommended.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Pediatric use	Not established for pediatric patients.
Geriatric use	Start at 5 mg once daily; titrate cautiously due to increased sensitivity.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NATURETIN-10 (NATURETIN-10).

Breastfeeding	No data on excretion in human milk. M/P ratio unknown. Potential for adverse effects in nursing infant, especially if high doses. Decision to breastfeed should consider maternal need and infant risk.
Teratogenic Risk	There is no data on NATURETIN-10 in pregnancy. Based on pharmacology, theoretical risk exists. First trimester: potential teratogenic effects cannot be ruled out. Second and third trimesters: may cause fetal renal impairment, oligohydramnios, and skull ossification delay.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Anuria","Hypersensitivity to bendroflumethiazide or sulfonamide-derived drugs","Hepatic coma or precoma","Severe renal impairment (CrCl <30 mL/min)"]